{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:35:56Z","timestamp":1793144156247,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T00:00:00Z","timestamp":1557532800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>We aimed to summarize existing data on the effectiveness of vedolizumab in extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD].<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic literature search in PubMed and the Cochrane Library, up to October 2018. Interventional and non-interventional studies as well as case-series studying vedolizumab and EIMs in adult patients with IBD were considered eligible.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three interventional studies [one randomized trial, n = 1032; and two open-label trials, n = 347], five non-interventional studies [n = 1496] and three case-series [n = 17] were included. Vedolizumab did not show any effectiveness in primary sclerosing cholangitis [PSC]. While no effect was seen in pre-existing manifestations regarding arthralgia and arthritis, the occurrence of new rheumatic symptoms was lower among vedolizumab users compared to placebo; occurrence was higher, however, with vedolizumab than with tumour necrosis factor inhibitors. Finally, vedolizumab appears not to be efficacious for the treatment of cutaneous manifestations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There is no strong evidence to suggest that vedolizumab may be efficacious for the treatment of pre-existing EIMs [especially PSC, rheumatic and cutaneous manifestations], although it may reduce the occurrence of new EIMs.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjz095","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T19:22:17Z","timestamp":1557429737000},"page":"1569-1577","source":"Crossref","is-referenced-by-count":49,"title":["Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review"],"prefix":"10.1093","volume":"13","author":[{"given":"Thomas","family":"Chateau","sequence":"first","affiliation":[{"name":"Department of Hepato-Gastroenterology, University Hospital of Grenoble, University of Grenoble Alpes, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6102-6579","authenticated-orcid":false,"given":"Stefanos","family":"Bonovas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"},{"name":"IBD Center, Humanitas Clinical and Research Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Le Berre","sequence":"additional","affiliation":[{"name":"Institut des Maladies de l\u2019Appareil Digestif, Nantes University Hospital, Nantes, France"},{"name":"Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, University of Lorraine, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, University Hospital of Grenoble, University of Grenoble Alpes, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"},{"name":"IBD Center, Humanitas Clinical and Research Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, University of Lorraine, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,10]]},"reference":[{"key":"2019121011172928600_CIT0001","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2019121011172928600_CIT0002","doi-asserted-by":"crossref","first-page":"17463","DOI":"10.3748\/wjg.v20.i46.17463","article-title":"Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients","volume":"20","author":"Zippi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2019121011172928600_CIT0003","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","article-title":"Extraintestinal manifestations and complications in IBD","volume":"10","author":"Ott","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2019121011172928600_CIT0004","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.3748\/wjg.v17.i22.2702","article-title":"Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome?","volume":"17","author":"Veloso","year":"2011","journal-title":"World J Gastroenterol"},{"key":"2019121011172928600_CIT0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2019121011172928600_CIT0006","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1016\/S1873-9946(13)60660-1","article-title":"P639 Influence of extraintestinal manifestations in health-related quality of life in inflammatory bowel disease patients","volume":"7","author":"Barreiro-de Acosta","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2019121011172928600_CIT0007","doi-asserted-by":"crossref","first-page":"A-355","DOI":"10.1016\/S0016-5085(09)61629-2","article-title":"M1126 Extraintestinal manifestations of inflammatory bowel disease and their impact on quality of life: results from the european collaborative study of inflammatory bowel disease (EC-IBD)","volume":"136","author":"Isene","year":"2009","journal-title":"Gastroenterology"},{"key":"2019121011172928600_CIT0008","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ibd.21472","article-title":"Risk of diagnosed fractures in children with inflammatory bowel diseases","volume":"17","author":"Kappelman","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2019121011172928600_CIT0009","first-page":"890","article-title":"Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease","volume":"16","author":"Andrisani","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2019121011172928600_CIT0010","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cgh.2016.10.001","article-title":"Implementing the concept of continuous clinical response into clinical practice for ulcerative colitis","volume":"15","author":"Peyrin-Biroulet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019121011172928600_CIT0011","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12178-011-9085-8","article-title":"Inflammatory bowel disease associated arthropathy","volume":"4","author":"Arvikar","year":"2011","journal-title":"Curr Rev Musculoskelet Med"},{"key":"2019121011172928600_CIT0012","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nri1784","article-title":"Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease","volume":"6","author":"Adams","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"2019121011172928600_CIT0013","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2019121011172928600_CIT0014","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2019121011172928600_CIT0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2019121011172928600_CIT0016","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study","author":"Caron","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2019121011172928600_CIT0017","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/apt.14829","article-title":"Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease","volume":"48","author":"Tse","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2019121011172928600_CIT0018","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/apt.14638","article-title":"Letter: Vedolizumab for autoimmune liver disease associated inflammatory bowel disease \u2013 Authors\u2019 reply","volume":"47","author":"Christensen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2019121011172928600_CIT0019","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","article-title":"Incidence of arthritis\/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials","volume":"13","author":"Feagan","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2019121011172928600_CIT0020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.14419","article-title":"Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort","volume":"47","author":"Tadbiri","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2019121011172928600_CIT0021","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1136\/annrheumdis-2016-211011","article-title":"Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease","volume":"76","author":"Orlando","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2019121011172928600_CIT0022","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy065","article-title":"Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease","author":"Dubinsky","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2019121011172928600_CIT0023","doi-asserted-by":"crossref","first-page":"S-360","DOI":"10.1016\/S0016-5085(18)31520-8","article-title":"Sa1696 - vedolizumab induces de novo extraintestinal manifestations in patients with inflammatory bowel disease","volume":"154","author":"Kim","year":"2018","journal-title":"Gastroenterology"},{"key":"2019121011172928600_CIT0024","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jbspin.2017.01.012","article-title":"Arthritis occurrence or reactivation under vedolizumab treatment for inflammatory bowel disease. A four cases report","volume":"85","author":"Wendling","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2019121011172928600_CIT0025","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1136\/annrheumdis-2016-211045","article-title":"Response to: \u2018Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease\u2019 by Orlando et al","volume":"76","author":"Varkas","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2019121011172928600_CIT0026","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","volume":"63","author":"Fleisher","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2019121011172928600_CIT0027","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrgastro.2012.125","article-title":"Paradoxical inflammation induced by anti-TNF agents in patients with IBD","volume":"9","author":"Cleynen","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2019121011172928600_CIT0028","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","article-title":"Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-\u03b1 agents","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2019121011172928600_CIT0029","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2010.07.022","article-title":"Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy","volume":"8","author":"Rahier","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019121011172928600_CIT0030","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2019121011172928600_CIT0031","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"2019121011172928600_CIT0032","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1684\/ejd.2011.1164","article-title":"Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis","volume":"21","author":"Gregoriou","year":"2011","journal-title":"Eur J Dermatol"},{"key":"2019121011172928600_CIT0033","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/1346-8138.13803","article-title":"Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy","volume":"45","author":"Suh","year":"2018","journal-title":"J Dermatol"},{"key":"2019121011172928600_CIT0034","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjd.13645","article-title":"Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients","volume":"173","author":"Jones","year":"2015","journal-title":"Br J Dermatol"},{"key":"2019121011172928600_CIT0035","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/kev263","article-title":"Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab","volume":"54","author":"\u010carija","year":"2015","journal-title":"Rheumatology"},{"key":"2019121011172928600_CIT0036","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1093\/ecco-jcc\/jjx002.741","article-title":"P617 Extraintestinal autoimmune phenomena during treatment with vedolizumab","volume":"11","author":"Lissner","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019121011172928600_CIT0037","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ajg.2017.395","article-title":"Pulmonary manifestation of Crohn\u2019s disease developed under treatment with vedolizumab","volume":"113","author":"Lissner","year":"2018","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjz095\/28810780\/jjz095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/13\/12\/1569\/31490555\/jjz095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/13\/12\/1569\/31490555\/jjz095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T03:40:59Z","timestamp":1607744459000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/13\/12\/1569\/5488014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,5,10]]},"published-print":{"date-parts":[[2019,12,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz095","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,5,10]]}}}